Mechanisms of Primary and Secondary Resistance to Immune Checkpoint Inhibitors in Cancer

Mechanisms of Primary and Secondary Resistance to Immune Checkpoint Inhibitors in Cancer

Blog Article

Immune checkpoint inhibitors (ICPis) have revolutionized cancer therapy with broad activities against a big boys tee wide range of malignancies.However, in many malignancies their efficacy remains limited due to the primary resistance.Furthermore, a high percentage of patients develop progression due to the secondary resistance even after obtaining a response or achieving a stable disease.In this review, we will discuss Building Supplies the mechanisms that underlie the primary and secondary resistance to ICPis in cancer immunotherapy and provide an overview to impart a broad understanding of the critical issues that are encountered in clinical oncology practice.